- FDA Issues Final Guidance on New Review Path for Safer Technologies
- FDA Continues to Target Unapproved COVID-19 Tests
- FDA Unveils Action Plan for Artificial Intelligence/Machine Learning Software
- Contract Manufacturer Fails to Document Nonconforming Product
- FDA Seeks Updated Labeling for Laparoscopic Power Morcellators
- Meitheal Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Cisatracurium Besylate Injection, USP 10mg per 5mL Due to Mislabeling
- Nostrum Laboratories, Inc. Expands Voluntary Nationwide Recall of Metformin HCl Extended Release Tablets, USP 750 mg, Due to N-Nitrosodimethylamine (NDMA) Content Above the Acceptable Daily Intake (ADI) Limit
- Boston Scientific Announces LOTUS Edge™ Aortic Valve System Voluntary Recall and Product Discontinuation
- Genetic Variants of SARS-CoV-2 May Lead to False Negative Results with Molecular Tests for Detection of SARS-CoV-2 - Letter to Clinical Laboratory Staff and Health Care Providers
- Fresenius Kabi Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP Due to the Presence of Particulate Matter
- Renewed Threat of Nuclear Holocaust Requires Physician Activism
- Roman Catholic Diocese of Brooklyn v. Cuomo — The Supreme Court and Pandemic Controls
- Testing in a Pandemic — Improving Access, Coordination, and Prioritization
- Incarceration and Social Death — Restoring Humanity in the Clinical Encounter
- Who Goes First? Government Leaders and Prioritization of SARS-CoV-2 Vaccines